4.7 Article

Targeting EGFR in Combination with Nutritional Supplements on Antitumor Efficacy in a Lung Cancer Mouse Model

期刊

MARINE DRUGS
卷 20, 期 12, 页码 -

出版社

MDPI
DOI: 10.3390/md20120751

关键词

anti-tumor signaling pathway; gefitinib; erlotinib; Lewis lung carcinoma; mice; selenium; fish oil

向作者/读者索取更多资源

This study found that the combination of selenium/fish oil with gefitinib or erlotinib significantly reduced tumor volume and weight in lung cancer treatment, and also reduced metastasis. Furthermore, the combination treatment modulated multiple signaling pathways and immune checkpoint molecules, reduced angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastasis, and proliferation, and increased cell cycle arrest and apoptosis.
Selenium (Se) and fish oil (FO) exert anti-epidermal growth factor receptor (EGFR) action on tumors. This study aimed to compare the anti-cancer efficacy of EGFR inhibitors (gefitinib and erlotinib) alone and in combination with nutritional supplements of Se/FO in treating lung cancer. Lewis LLC1 tumor-bearing mice were treated with a vehicle or Se/FO, gefitinib or gefitinib plus Se/FO, and erlotinib or erlotinib plus Se/FO. The tumors were assessed for mRNA and protein expressions of relevant signaling molecules. Untreated tumor-bearing mice had the lowest body weight and highest tumor weight and volume of all the mice. Mice receiving the combination treatment with Se/FO and gefitinib or erlotinib had a lower tumor volume and weight and fewer metastases than did those treated with gefitinib or erlotinib alone. The combination treatment exhibited greater alterations in receptor signaling molecules (lower EGFR/TGF-beta/T beta R/AXL/Wnt3a/Wnt5a/FZD7/beta-catenin; higher GSK-3 beta) and immune checkpoint molecules (lower PD-1/PD-L1/CD80/CTLA-4/IL-6; higher NKp46/CD16/CD28/IL-2). These mouse tumors also had lower angiogenesis, cancer stemness, epithelial to mesenchymal transitions, metastases, and proliferation of Ki-67, as well as higher cell cycle arrest and apoptosis. These preliminary results showed the Se/FO treatment enhanced the therapeutic efficacies of gefitinib and erlotinib via modulating multiple signaling pathways in an LLC1-bearing mouse model.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据